OBJECTIVE: To validate the simplest approach to preparing patients with differentiated thyroid carcinoma (DTC) for (131) I-administration ((131) I-A), minimizing the impact of hypothyroidism. DESIGN: Panel study. PATIENTS: Ninety patients with DTC were enrolled in the study. Sixty (Group A) underwent total thyroidectomy (TT); L-T4 was not administered in preparation for (131) I-A planned for 3 weeks later. Thirty patients (Group B) with previous TT and (131) I-A stopped L-T4 in preparation for clinical evaluation, including whole-body scanning (WBS)/radioiodine therapy during thyrotrophin (TSH) stimulation planned for 3 weeks (or more) later. MEASUREMENTS: Thyrotrophin was measured the day before TT for group A, dur...
Introduction: It's difficult to make a scientific, evidence-based approach about the timing of radio...
CONTEXT: After surgery for differentiated thyroid carcinoma, many patients are treated with radioiod...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...
OBJECTIVE: To validate the simplest approach to preparing patients with differentiated thyroid c...
Context: No consensus exists about the optimal duration of the low-iodine diet (LID) in the preparat...
Objective: In intermediate risk DTC (IR-DTC) patients, selective use of radioiodine (131-I) for remn...
For many years the recommended therapy for differentiated thyroid carcinoma (DTC), with the exceptio...
Background: Most current guidelines suggest one or two weeks of low iodine diet (LID) before radioac...
Objectives Radioiodine can be applied for remnant ablation in low and low to intermediate-risk patie...
Radioiodine (131I iodide) has long been a safe, effective and widely used treatment in the managemen...
Objective: Recently, a multicenter study in differentiated thyroid cancer (DTC) patients showed that...
- AIM: to determine whether the first three months after 131I ablation is too early to perform radio...
Introduction: Retention of I-131 in the body of patients with differentiated thyroid carcinoma (DTC)...
Background Well-differentiated thyroid cancers (DTC) are common endocrine cancers. They originate f...
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy with the highest mortali...
Introduction: It's difficult to make a scientific, evidence-based approach about the timing of radio...
CONTEXT: After surgery for differentiated thyroid carcinoma, many patients are treated with radioiod...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...
OBJECTIVE: To validate the simplest approach to preparing patients with differentiated thyroid c...
Context: No consensus exists about the optimal duration of the low-iodine diet (LID) in the preparat...
Objective: In intermediate risk DTC (IR-DTC) patients, selective use of radioiodine (131-I) for remn...
For many years the recommended therapy for differentiated thyroid carcinoma (DTC), with the exceptio...
Background: Most current guidelines suggest one or two weeks of low iodine diet (LID) before radioac...
Objectives Radioiodine can be applied for remnant ablation in low and low to intermediate-risk patie...
Radioiodine (131I iodide) has long been a safe, effective and widely used treatment in the managemen...
Objective: Recently, a multicenter study in differentiated thyroid cancer (DTC) patients showed that...
- AIM: to determine whether the first three months after 131I ablation is too early to perform radio...
Introduction: Retention of I-131 in the body of patients with differentiated thyroid carcinoma (DTC)...
Background Well-differentiated thyroid cancers (DTC) are common endocrine cancers. They originate f...
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy with the highest mortali...
Introduction: It's difficult to make a scientific, evidence-based approach about the timing of radio...
CONTEXT: After surgery for differentiated thyroid carcinoma, many patients are treated with radioiod...
Background: In differentiated thyroid cancer (DTC) patients at intermediate risk of recurrences, no ...